OBJECTIVE: To determine whether serologic evidence of Chlamydia trachomatis during pregnancy is a risk factor for preterm delivery (before 37 weeks' gestation). DESIGN: Chart review. SETTING: Antenatal clinics associated with a teaching hospital. PATIENTS: A group of 103 unselected consecutive patients presenting for routine prenatal care. OUTCOME MEASURES: Pregnancy outcome and C. trachomatis serologic status. RESULTS: A total of 21 women (20%) were found to be seropositive for IgG antibodies to C. trachomatis. They were similar to the seronegative women with respect to maternal age, parity, history of preterm birth, obstetric or medical problems, smoking status, history of drug abuse, educational status and psychosocial stressors. The seropositive women were significantly more likely than the seronegative women to have a preterm birth (24% [5/21] v. 7% [6/82]i p = 0.029, odds ratio 3.96, 95% confidence interval 1.08 to 14.57), an infant with a lower mean gestational age at birth (262 [standard deviation (SD) 19] days v. 273 [SD 15] days; p = 0.0052) and an infant with a lower mean birth weight (3125 [SD 692] g v. 3473 [SD 696] g; p = 0.0434). The positive predictive value of a seropositive result for preterm birth was 31% (5/16); the negative predictive value of a seronegative result for preterm birth was 8% (6/76). CONCLUSION: Women with serologic evidence of C. trachomatis may be at risk for preterm birth. Further study is required to determine whether serologic testing for C. trachomatis should be a routine part of prenatal care.
OBJECTIVE: To determine whether serologic evidence of Chlamydia trachomatis during pregnancy is a risk factor for preterm delivery (before 37 weeks' gestation). DESIGN: Chart review. SETTING: Antenatal clinics associated with a teaching hospital. PATIENTS: A group of 103 unselected consecutive patients presenting for routine prenatal care. OUTCOME MEASURES: Pregnancy outcome and C. trachomatis serologic status. RESULTS: A total of 21 women (20%) were found to be seropositive for IgG antibodies to C. trachomatis. They were similar to the seronegative women with respect to maternal age, parity, history of preterm birth, obstetric or medical problems, smoking status, history of drug abuse, educational status and psychosocial stressors. The seropositive women were significantly more likely than the seronegative women to have a preterm birth (24% [5/21] v. 7% [6/82]i p = 0.029, odds ratio 3.96, 95% confidence interval 1.08 to 14.57), an infant with a lower mean gestational age at birth (262 [standard deviation (SD) 19] days v. 273 [SD 15] days; p = 0.0052) and an infant with a lower mean birth weight (3125 [SD 692] g v. 3473 [SD 696] g; p = 0.0434). The positive predictive value of a seropositive result for preterm birth was 31% (5/16); the negative predictive value of a seronegative result for preterm birth was 8% (6/76). CONCLUSION:Women with serologic evidence of C. trachomatis may be at risk for preterm birth. Further study is required to determine whether serologic testing for C. trachomatis should be a routine part of prenatal care.
Authors: D H Martin; L Koutsky; D A Eschenbach; J R Daling; E R Alexander; J K Benedetti; K K Holmes Journal: JAMA Date: 1982-03-19 Impact factor: 56.272
Authors: G I J G Rours; R P Verkooyen; H F M Willemse; E A E van der Zwaan; A van Belkum; R de Groot; H A Verbrugh; J M Ossewaarde Journal: J Clin Microbiol Date: 2005-09 Impact factor: 5.948
Authors: P Christian; S K Khatry; S C LeClerq; A A Roess; L Wu; J D Yuenger; J M Zenilman Journal: Sex Transm Infect Date: 2005-06 Impact factor: 3.519
Authors: Sarah C Woodhall; Rachel J Gorwitz; Stephanie J Migchelsen; Sami L Gottlieb; Patrick J Horner; William M Geisler; Catherine Winstanley; Katrin Hufnagel; Tim Waterboer; Diana L Martin; Wilhelmina M Huston; Charlotte A Gaydos; Carolyn Deal; Magnus Unemo; J Kevin Dunbar; Kyle Bernstein Journal: Lancet Infect Dis Date: 2018-07-05 Impact factor: 25.071
Authors: G Ingrid J G Rours; Liesbeth Duijts; Henriette A Moll; Lidia R Arends; Ronald de Groot; Vincent W Jaddoe; Albert Hofman; Eric A P Steegers; Johan P Mackenbach; Alewijn Ott; Hendrina F M Willemse; Elizabeth A E van der Zwaan; Roel P Verkooijen; Henri A Verbrugh Journal: Eur J Epidemiol Date: 2011-05-03 Impact factor: 8.082
Authors: G I J G Rours; Tamar Anne Smith-Norowitz; Jared Ditkowsky; Margaret R Hammerschlag; R P Verkooyen; R de Groot; H A Verbrugh; M J Postma Journal: Pathog Glob Health Date: 2016 Oct - Dec Impact factor: 2.894
Authors: G Ingrid J G Rours; Ronald R de Krijger; Alewijn Ott; Hendrina F M Willemse; Ronald de Groot; Luc J I Zimmermann; Renee F Kornelisse; Henri A Verbrugh; Roel P Verkooijen Journal: Eur J Epidemiol Date: 2011-03-24 Impact factor: 8.082